4th Quarter - Report
ARENTFOX SCHIFF LLP for CSL BEHRING
Firm
Client
Income
$20,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Orphan drug exclusion within the pharmaceutical tax in the Patient Protection and Affordable Care Act H.R. 2672 (Preserving Access to Orphan Drugs Act of 2011), all provisions
Foreign entity interest: CSL Limited, identified in the LD-1, is interested in U.S. tax policies that may affect the business of its subsidiary CSL Behring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JON BOUKER | — |
| PHILIP ENGLISH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.